Science & Technology
Biotechnology
Medical Biotechnology: Insulin, Vaccines, Antibodies and Diagnostics
Recombinant insulin, vaccine platforms and India's COVID vaccines, monoclonal antibodies, molecular diagnostics, biosimilars and CAR-T for CGPSC.
Prerequisites
- Genetic Engineering: Tools and Recombinant DNA Technology — how a gene is moved into a microbe.
- Genome Editing, Gene Therapy, Cloning and Genomics — gene therapy and CRISPR.
- Life Science and Human Health — immunity, antigens and antibodies.
The Hook: Six Vaccines in One Pandemic
Connect
In 2021, at a vaccination centre in Durg or Jagdalpur, you were offered Covishield or Covaxin. A few months later India approved ZyCoV-D, given without a needle, and in 2022 an Indian mRNA vaccine. Each one was built on a different biotechnology platform — an inactivated virus, a harmless carrier virus, a DNA ring, a messenger RNA.
How do these platforms differ? And how is the same set of tools used to make insulin, cancer antibodies and a ₹500 diagnostic kit? This page answers those questions.
Why it matters: “Which vaccine uses which platform”, “who discovered monoclonal antibodies”, “ELISA detects…” are classic Prelims items. Mains P-IV asks how biotechnology can strengthen public health, often with an India or Chhattisgarh lens.
Recombinant Therapeutics
| Product | Key facts |
|---|---|
| Human insulin | Insulin has two chains, A and B, joined by disulphide bridges. In the body it is made as pro-insulin with an extra C-peptide that is removed. Recombinant human insulin (Humulin) was the first rDNA drug approved, in the USA in 1982; NCERT credits Eli Lilly (1983) with making the A and B chains separately in E. coli and joining them. It replaced insulin from cattle and pigs, which caused allergies in some patients |
| Human growth hormone | Recombinant production for growth disorders |
| Erythropoietin (EPO) | For anaemia in kidney disease |
| Interferons | Antiviral and anticancer proteins |
| Clotting factors | Factor VIII and IX for haemophilia |
| Tissue plasminogen activator (tPA) | Clot-dissolving drug for heart attack and stroke |
Biosimilars
A biosimilar is a biological drug highly similar to an already approved biological (reference) product, made after patent expiry. Unlike chemical generics, biologicals cannot be copied exactly because they are made in living cells. India is a major producer of biosimilars (insulins, monoclonal antibodies), which lowers treatment costs. India’s biosimilar guidelines are issued jointly by CDSCO and DBT.
Vaccines (टीका) and Their Platforms
A vaccine trains the immune system using a harmless form or part of a pathogen, so that memory cells respond quickly to a real infection.
| Platform | How it works | Examples |
|---|---|---|
| Live attenuated | Weakened live pathogen | Oral polio (OPV), BCG, MMR |
| Inactivated (killed) | Whole pathogen killed by heat or chemicals | Covaxin (Bharat Biotech with ICMR-NIV, Pune), injectable polio (IPV) |
| Recombinant subunit / protein | Only a protein of the pathogen, made in yeast or other cells by rDNA | Hepatitis B vaccine (surface antigen made in yeast — the classic first recombinant vaccine); Corbevax (Biological E, receptor-binding domain protein); HPV vaccines including India’s Cervavac (Serum Institute, 2022) |
| Viral vector | A harmless carrier virus delivers a gene for the pathogen’s protein | Covishield (Serum Institute; Oxford–AstraZeneca ChAdOx1 chimpanzee adenovirus); Sputnik V |
| DNA vaccine | A DNA plasmid carrying the antigen gene is injected; the body’s cells make the antigen | ZyCoV-D (Zydus Cadila) — world’s first plasmid DNA vaccine for COVID-19, EUA on 20 August 2021; three doses, given with a needle-free injector |
| mRNA vaccine | Messenger RNA in lipid nanoparticles instructs cells to make the antigen; no DNA enters the nucleus | Pfizer–BioNTech, Moderna; GEMCOVAC-19 (Gennova Biopharmaceuticals, Pune) — India’s first mRNA vaccine, EUA on 29 June 2022 |
| Intranasal | Given through the nose to build mucosal immunity | iNCOVACC (Bharat Biotech, 2022) |
Nobel link
The 2023 Nobel Prize in Physiology or Medicine went to Katalin Karikó and Drew Weissman for nucleoside-base modifications that made mRNA vaccines effective against COVID-19.
Monoclonal Antibodies (एकक्लोनी प्रतिपिंड)
| Point | Detail |
|---|---|
| What they are | Identical antibodies, all from one clone of cells, that bind one specific antigen (epitope) |
| How made | Hybridoma technology: an antibody-producing B-lymphocyte is fused with a myeloma (cancer) cell, giving a hybrid that both makes the antibody and divides indefinitely |
| Discovered by | Georges Köhler and César Milstein (1975); they shared the 1984 Nobel Prize in Medicine (with Niels Jerne) |
| Uses | Cancer therapy (e.g. trastuzumab for breast cancer), autoimmune disorders, organ-transplant rejection, pregnancy test kits, rapid antigen tests, blood-typing reagents |
Molecular Diagnostics
| Technique | Principle | Example uses |
|---|---|---|
| ELISA (enzyme-linked immunosorbent assay) | Antigen–antibody reaction detected by an enzyme-linked colour change | HIV antibody screening, dengue, hepatitis |
| PCR / RT-PCR | Amplifies very small amounts of pathogen DNA/RNA | COVID-19, tuberculosis (e.g. TrueNat, CBNAAT), HIV viral load; detects infection before symptoms or antibodies appear |
| DNA probes | A labelled single-stranded DNA binds its complementary sequence | Detecting mutant genes, e.g. in cancer or genetic disorders |
| Rapid antigen tests / lateral flow | Monoclonal antibodies capture the antigen on a strip | COVID-19, malaria, pregnancy |
| Point-of-care tests for sickle cell | Simple solubility tests and rapid kits; HPLC or electrophoresis to confirm | Population screening in tribal districts |
Advanced Therapies
| Therapy | What it is | Indian landmark |
|---|---|---|
| CAR-T cell therapy | The patient’s T cells are genetically engineered to carry a chimeric antigen receptor (CAR) that recognises cancer cells, then infused back | NexCAR19 (ImmunoACT; IIT Bombay + Tata Memorial Centre) — India’s first, approved by CDSCO in October 2023 for certain B-cell lymphomas and leukaemias, at a fraction of the cost of imported CAR-T |
| Gene therapy | Delivering a correct gene | First-in-human haemophilia A gene therapy trial at CMC Vellore (DBT-supported) |
| CRISPR therapy | Editing the patient’s own stem cells | BIRSA 101 for sickle cell disease (CSIR-IGIB, unveiled November 2025) |
| Stem-cell transplant | Bone-marrow / blood stem cells replace diseased blood-forming cells | Established treatment for thalassaemia, sickle cell disease and some cancers |
| Pharmacogenomics | Choosing drugs and doses according to a person’s genes | Builds on Genome India data |
Other Health-Related Biotechnology
- Transgenic animals as models of human disease (cancer, Alzheimer’s) and as “bioreactors” producing human proteins in milk.
- Probiotics and fermentation: antibiotics such as penicillin (Alexander Fleming, 1928) are microbial products; large-scale production uses industrial fermentation.
- Bioremediation of hospital and industrial waste using microbes.
- One Health surveillance: genome sequencing of pathogens (the INSACOG consortium sequenced SARS-CoV-2 variants in India).
Chhattisgarh angle for Mains
- Sickle cell disease: a major public-health burden in the state’s tribal and rural population; free testing and treatment through district hospitals, medical colleges and the Sickle Cell Institute Chhattisgarh, Raipur, under the national Sickle Cell Anaemia Elimination Mission (2023–2047). Molecular diagnosis, newborn screening, hydroxyurea and, in future, gene therapy are all biotech links.
- Malaria and TB in Bastar and Surguja: rapid diagnostic kits (monoclonal-antibody based) and molecular TB tests bring diagnosis to the village level.
- AIIMS Raipur and the state’s medical colleges carry out molecular diagnostics and genome-based research.
Analysis for Mains: Biotechnology and Public Health
| Opportunities | Challenges |
|---|---|
| India as “pharmacy of the world”: vaccines and biosimilars at low cost | Affordability of cutting-edge therapies (CAR-T, gene therapy) |
| Indigenous platforms proved themselves during COVID-19 (six-plus vaccines) | Regulatory capacity — CDSCO approvals, post-marketing surveillance |
| Molecular diagnostics enable early detection in remote areas | Cold chain and lab infrastructure in tribal districts |
| Genomics enables precision medicine for Indian populations | Vaccine hesitancy and misinformation |
| BioE3 policy and BIRAC support for biotech start-ups | Bioethics: consent, data privacy, equitable trial participation |
Memory Tricks
COVID vaccine platforms: 'Covaxin Kills, Covishield Carries, ZyCoV Delivers DNA, GEMCOVAC Gives mRNA, Corbevax is Core-protein'
- Covaxin — killed (inactivated) virus
- Covishield — carrier (viral vector)
- ZyCoV-D — D for DNA; needle-free; 2021
- GEMCOVAC — Gennova, Genetic messenger (mRNA); 2022
- Corbevax — core protein (subunit)
Monoclonal = 'Mono' + 'Clone'
One antigen target, one clone of cells. Köhler and Milstein: “Kill Malignancy” — their antibodies are now cancer drugs. Year 1975.
Don’t Confuse
| This | vs | That |
|---|---|---|
| ZyCoV-D — plasmid DNA vaccine (Zydus, 2021) | vs | GEMCOVAC-19 — mRNA vaccine (Gennova, 2022) |
| Covaxin — inactivated whole virus | vs | Covishield — viral vector |
| Vaccine — prevents disease by training immunity | vs | Monoclonal antibody — ready-made antibody given as treatment (passive) |
| ELISA — detects antigen or antibody | vs | PCR — detects nucleic acid (DNA/RNA) |
| Biosimilar — similar copy of a biological | vs | Generic — exact copy of a chemical drug |
| Insulin A and B chains — joined by disulphide bonds | vs | C-peptide — removed during maturation |
Common Mistakes
MCQ traps
- “mRNA vaccines alter human DNA.” False. mRNA stays in the cytoplasm, is translated and then broken down; it does not enter the nucleus.
- “Covaxin is an mRNA vaccine.” False. Covaxin is an inactivated whole-virus vaccine.
- “ZyCoV-D was the world’s first mRNA vaccine.” False. It was the world’s first plasmid DNA vaccine for COVID-19 (August 2021).
- “Monoclonal antibodies are produced from several types of B cells.” False. That describes polyclonal antibodies; monoclonal antibodies come from one clone.
- “PCR can detect HIV only after antibodies appear.” False. PCR detects the virus’s genetic material, so it works before an antibody test turns positive.
Practice
All questions below are original practice questions written in CGPSC style. They are not previous-year questions.
Level 1: Foundation
- The two chains of the insulin molecule are joined by ______ bridges.
- Monoclonal antibodies are produced by ______ technology.
- India’s first mRNA vaccine, approved in 2022, is ______.
Answers
- Disulphide bridges.
- Hybridoma technology (Köhler and Milstein, 1975).
- GEMCOVAC-19 (Gennova Biopharmaceuticals, Pune).
Level 2: Prelims MCQs
Q1. Consider the following statements:
- ZyCoV-D was the world’s first plasmid DNA vaccine to receive emergency use authorisation for COVID-19.
- Covaxin is a viral-vector vaccine.
- The Nobel Prize in Physiology or Medicine 2023 recognised work that enabled mRNA vaccines.
Which of the statements given above is/are correct?
- (a) 1 only
- (b) 1 and 2 only
- (c) 1 and 3 only
- (d) 2 and 3 only
Answer and explanation
(c) 1 and 3 only. ZyCoV-D (Zydus Cadila) received EUA on 20 August 2021 as the world’s first plasmid DNA COVID-19 vaccine. Covaxin is an inactivated vaccine; Covishield is the viral-vector vaccine. Karikó and Weissman won the 2023 Medicine Nobel for the mRNA modification work.
Q2. Match List I (Vaccine) with List II (Platform):
| List I | List II |
|---|---|
| A. Covishield | 1. Protein subunit |
| B. Corbevax | 2. mRNA |
| C. GEMCOVAC-19 | 3. Inactivated virus |
| D. Covaxin | 4. Viral vector |
- (a) A-4, B-1, C-2, D-3
- (b) A-1, B-4, C-2, D-3
- (c) A-4, B-2, C-1, D-3
- (d) A-3, B-1, C-2, D-4
Answer and explanation
(a) A-4, B-1, C-2, D-3. Covishield uses a chimpanzee adenovirus vector; Corbevax is a receptor-binding-domain protein subunit; GEMCOVAC-19 is mRNA; Covaxin is inactivated whole virus.
Q3. Hybridoma cells used to produce monoclonal antibodies are formed by fusing:
- (a) A T-lymphocyte with a red blood cell
- (b) A B-lymphocyte with a myeloma cell
- (c) A macrophage with a bacterium
- (d) Two embryonic stem cells
Answer and explanation
(b). The B-lymphocyte contributes the ability to make one specific antibody; the myeloma (cancer) cell contributes unlimited division. The hybrid makes the antibody indefinitely.
Q4. NexCAR19, approved in India in 2023, is:
- (a) A recombinant insulin analogue
- (b) An indigenous CAR-T cell therapy for certain blood cancers
- (c) A malaria vaccine developed at AIIMS Raipur
- (d) A rapid antigen test for tuberculosis
Answer and explanation
(b). NexCAR19 was developed by IIT Bombay and Tata Memorial Centre and commercialised by ImmunoACT; CDSCO approved it in October 2023 for relapsed/refractory B-cell lymphomas and leukaemias.
Q5. Which test is based on the antigen–antibody reaction?
- (a) PCR
- (b) DNA fingerprinting
- (c) ELISA
- (d) Gel electrophoresis
Answer and explanation
(c) ELISA. ELISA detects antigens or antibodies using an enzyme-linked colour reaction. PCR and DNA fingerprinting work on nucleic acids; electrophoresis separates molecules by size and charge.
Level 3: Mains Answer Writing
Q1. (60 words) What are monoclonal antibodies? Give two applications.
Model answer outline
- Definition: identical antibodies from a single clone, specific to one antigen; produced by hybridoma technology (Köhler and Milstein, 1975).
- Applications: targeted cancer therapy (e.g. trastuzumab); diagnostics such as pregnancy kits and rapid antigen tests; preventing transplant rejection (any two).
Q2. (150–200 words) How has biotechnology strengthened India’s public-health response? Illustrate with recent examples and suggest how Chhattisgarh can benefit.
Model answer outline
- Intro: biotechnology converts biological knowledge into vaccines, drugs and diagnostics; COVID-19 was its large-scale test.
- Examples:
- Vaccines on multiple platforms: Covaxin, Covishield, Corbevax, ZyCoV-D (first DNA vaccine, 2021), GEMCOVAC-19 (first Indian mRNA vaccine, 2022); Cervavac for cervical cancer.
- Therapies: affordable recombinant insulin and biosimilars; NexCAR19 (2023); BIRSA 101 for sickle cell (2025).
- Diagnostics: RT-PCR network, molecular TB tests, rapid malaria kits; genomic surveillance through INSACOG.
- Chhattisgarh: sickle cell screening and care (Sickle Cell Institute, Raipur; national mission 2023–2047); malaria and TB diagnosis in Bastar and Surguja; capacity at AIIMS Raipur.
- Challenges: cost of advanced therapies, cold chain, regulatory capacity, hesitancy.
- Conclusion: public funding, BIRAC-backed start-ups and last-mile delivery can make biotech a tool of health equity.
Quick Revision Table
| Fact | Detail |
|---|---|
| Insulin | A + B chains, disulphide bridges; pro-insulin has C-peptide |
| First rDNA drug | Human insulin (Humulin), USA 1982; NCERT: Eli Lilly 1983 |
| First recombinant vaccine | Hepatitis B (surface antigen in yeast) |
| Covaxin | Inactivated; Bharat Biotech + ICMR-NIV |
| Covishield | Viral vector (ChAdOx1); Serum Institute |
| Corbevax | Protein subunit; Biological E |
| ZyCoV-D | World’s first plasmid DNA COVID vaccine; EUA 20 Aug 2021; needle-free |
| GEMCOVAC-19 | India’s first mRNA vaccine; Gennova, Pune; EUA 29 June 2022 |
| Cervavac | India’s indigenous HPV vaccine; Serum Institute, 2022 |
| Nobel 2023 Medicine | Karikó and Weissman — mRNA vaccines |
| Monoclonal antibodies | Hybridoma; Köhler and Milstein 1975; Nobel 1984 |
| ELISA | Antigen–antibody reaction |
| NexCAR19 | India’s first CAR-T; CDSCO Oct 2023 |
| Biosimilar | Similar (not identical) copy of a biological drug |
Key Takeaways
Key Takeaways
- Recombinant DNA made human proteins (insulin, growth hormone, clotting factors) safe and abundant.
- Learn vaccines by platform: inactivated, subunit, viral vector, DNA, mRNA — India has examples of each.
- Monoclonal antibodies (hybridoma, 1975) are both diagnostic tools and targeted drugs.
- Molecular diagnostics (PCR, ELISA, rapid tests) bring early detection to remote districts.
- India’s frontier: CAR-T (NexCAR19), gene therapy (CMC Vellore) and CRISPR (BIRSA 101) — the challenge is affordability and access.
What’s Next
- Regulation, Policy and Ethics — DBT, BIRAC, BioE3 and the ethics of biotech
- Biotechnology — Quick Revision — the whole chapter on one page
- Life Science and Human Health — diseases, immunity and nutrition
- Welfare Programmes — health schemes that deliver these technologies
Advertisement